Main Story
-
The Developing Doctor Launches CME-Accredited Course to Enhance Physician Wellbeing
Iowa City, IOWA, June 24, 2026 (GLOBE NEWSWIRE) — The Developing Doctor has unveiled its latest self-paced course, “Mastery & Wellness: How to Thrive as a Physician,” now approved for 12 physician CME credits. This course is jointly provided with the Postgraduate Institute for Medicine (PIM), making it eligible for reimbursement through most institutional CME…
Automobile
Tech
Entertainment
-
Dance Without Borders: BYU Ballroom Dance Gives Historic Performances in India
New Delhi | Bengaluru, India The BYU Ballroom Dance Company lit up stages in India for the first time, enchanting over 1,000 audience members with show-stopping performances held on 4 and 6 June 2026 in the nation’s capital and a grand finale in Bengaluru on 9 June. Distinguished guests, including government, interfaith, and community leaders,…
Health
-
The Developing Doctor Launches CME-Accredited Course to Enhance Physician Wellbeing
Iowa City, IOWA, June 24, 2026 (GLOBE NEWSWIRE) — The Developing Doctor has unveiled its latest self-paced course, “Mastery & Wellness: How to Thrive as a Physician,” now approved for 12 physician CME credits. This course is jointly provided with the Postgraduate Institute for Medicine (PIM), making it eligible for reimbursement through most institutional CME…
-
REPROCELL Submits Application for Manufacturing and Marketing Approval in Japan for Stem Cell Therapy Stemchymal® for Spinocerebellar Ataxia (SCA3 and SCA6)
YOKOHAMA, Japan, June 24, 2026 /PRNewswire/ — REPROCELL Inc. today announced the submission of an application for manufacturing and marketing approval in Japan for the regenerative medicine product Stemchymal®, for which the company holds exclusive commercialization rights in Japan. The application seeks approval for the use of Stemchymal® to suppress the progression of ataxia in…
-
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
– First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQTORZI, a next-generation PD-1 inhibitor – June 23, 2026 14:00 ET | Source: Coherus Oncology, Inc. REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) — Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. (“Zumutor”), an immuno-oncology biotech…
-
TraceLink Named Fortress Cybersecurity Awards Finalist for Enabling the Transformation to a Secure, Auditable Agentic Supply Chain Operating Model
OPUS Platform and OPUS Agents recognized for enabling no-code AI agents to operate as permissioned, traceable participants in regulated pharmaceutical supply chain operations Summary TraceLink has been named a finalist in the 2026 Fortress Cybersecurity Awards for OPUS and OPUS Agents. The recognition highlights TraceLink’s ability to support agentic supply chain operations in one of…
-
Dyne Therapeutics Appoints Barry Greene to Board of Directors
June 22, 2026 16:10 ET | Source: Dyne Therapeutics, Inc. WALTHAM, Mass., June 22, 2026 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Barry Greene to its Board of Directors. Mr. Greene brings more…
-
Texas A&M Study Highlights Pictor PictVet® as a Promising New Tool for Non-Invasive Beef Cattle Health Monitoring
Independent peer-reviewed research published in Frontiers in Veterinary Science reports strong assay performance in a proof-of-concept evaluation using bovine nasopharyngeal swab samples CARLSBAD, Calif., June 22, 2026 /PRNewswire/ — Pictor Holdings Inc., a global targeted proteomic platform company, today highlighted the publication of an independent peer-reviewed study conducted by researchers at Texas A&M University and published…
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
